People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

anxiety, vomiting, feeling drunk, increased blood pressure, and sedation. No new safety signals were identified in the trial. Spravato is classified as a Schedule III controlled substance and is ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Common AEs include temporary increased blood pressure; issues with thinking clearly; bladder problems; nausea; dizziness; drowsiness; numbness; anxiety; lack of energy; headache; increased feelings of ...

Spravato has a list of potential side effects, including disassociation, dizziness, nausea, sedation, vertigo, decreased feeling or sensitivity, anxiety, lethargy, increased blood pressure ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...

The UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal spray Spravato on the NHS, because of cost and clinical concerns.

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA ...